Pfizer (NYSE:PFE) Shares Up 0.2% – Here’s Why

Shares of Pfizer Inc. (NYSE:PFE) shot up 0.2% during mid-day trading on Friday . The company traded as high as $25.08 and last traded at $25.06. 8,885,026 shares traded hands during trading, a decline of 76% from the average session volume of 36,714,311 shares. The stock had previously closed at $25.01.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on PFE. Citigroup cut their price target on Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a report on Tuesday, January 28th. Truist Financial decreased their target price on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research note on Wednesday, December 18th. Bank of America reissued a “neutral” rating and issued a $29.00 price objective on shares of Pfizer in a research note on Tuesday, December 10th. Guggenheim reissued a “buy” rating on shares of Pfizer in a report on Tuesday, March 18th. Finally, Hsbc Global Res raised Pfizer to a “strong-buy” rating in a research note on Monday, March 10th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating, six have given a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $31.92.

Pfizer Stock Up 0.8 %

The firm has a market cap of $142.93 billion, a P/E ratio of 17.87, a price-to-earnings-growth ratio of 0.64 and a beta of 0.61. The company’s 50-day simple moving average is $26.06 and its 200 day simple moving average is $26.92. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, topping the consensus estimate of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company had revenue of $17.76 billion during the quarter, compared to analyst estimates of $17.26 billion. During the same quarter last year, the business posted $0.10 earnings per share. The firm’s revenue was up 24.7% on a year-over-year basis. Research analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Insider Activity

In other news, Director Ronald E. Blaylock acquired 19,457 shares of the company’s stock in a transaction on Thursday, February 13th. The stock was bought at an average cost of $25.65 per share, with a total value of $499,072.05. Following the completion of the purchase, the director now directly owns 27,707 shares of the company’s stock, valued at $710,684.55. This represents a 235.84 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 0.06% of the company’s stock.

Institutional Investors Weigh In On Pfizer

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Avant Financial Advisors LLC bought a new position in shares of Pfizer during the fourth quarter valued at approximately $332,000. Fire Capital Management LLC purchased a new position in Pfizer during the 4th quarter valued at $1,018,000. Mascagni Wealth Management Inc. bought a new position in Pfizer in the 4th quarter valued at $51,000. DSG Capital Advisors LLC purchased a new stake in Pfizer in the fourth quarter worth $281,000. Finally, Chancellor Financial Group WB LP bought a new stake in shares of Pfizer during the fourth quarter worth $290,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.